Old Web
English
Sign In
Acemap
>
Paper
>
MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
2021
B.C. Cho
Robert C. Doebele
Jessica J. Lin
Misako Nagasaka
Christina S. Baik
A J van der Wekken
Vamsidhar Velcheti
K H Lee
Shan Liu
Ben Solomon
S. Kao
Matthew G Krebs
Viola W. Zhu
S. Stopatschinskaja
R. Camidge
A. Drilon
Keywords:
Medicine
Nuclear medicine
Trident
in patient
Phase (matter)
ROS1
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI
[]